The Centers for Disease Control and Prevention asked state governors last week to fast track applications for building permits for vaccine distribution sites that would be up and running in early November, around the same time as Election Day.
The minister said, "We have not yet received the vaccine and, to the best of my knowledge, it is not yet ready". Vaccine development usually takes years, yet Covid-19 shots are progressing at a rapid pace as companies and countries rush to stop the spread of the coronavirus.
A Nurse gives a volunteer an injection, as the world's biggest study of a possible COVID-19 vaccine, developed by the US National Institutes of Health and Moderna Inc., gets underway on July 27, 2020, in Binghamton, NY. Russian Federation licensed the two-shot jab for domestic use in August, the first country to do so and before any data had been published or a large-scale trial begun.
They said that the immune reaction elicited by the vaccine "bodes well" but that "efficacy for any COVID-19 vaccine has not yet been shown".
For many vaccine candidates, phase III is only beginning, and it will be the real test of their efficacy, Swaminathan said.
The vaccine is based on weakened versions of adenoviruses - a group of viruses that typically infect membranes of the eyes, respiratory tract, urinary tract, intestines and nervous system, and include the common cold.
The scheme has 9 Covid-19 vaccine candidates covering a range of technologies and scientific approaches.
Phase 3 studies, which are the final stages of testing, are created to prove whether the shots can reduce rates of symptomatic Covid-19 disease compared with people without vaccination.
The Russia Direct Investment Fund, a sovereign wealth fund created by the Russian government for joint partnerships, had last month signalled its intention to conduct clinical trials and seek mass production of the vaccine in India.
Governments and big pharmaceutical firms are racing to develop a vaccine to end the COVID-19 pandemic, which has killed more than 850,000 people globally and infected around 26 million.
Dmitriev said vaccine production "will initially be aimed at a Russian market, but we hope to have the possibility to supply the vaccine to an global market", signaling interest from around 40 countries.
According to the published report, two forms of the vaccine were analyzed, frozen for large-scale use, and lyophilized (freeze-dried) to be delivered in hard-to-reach areas of the world. "I want to reiterate my commitment that we are putting science and the interest of society at the heart of our work", he said.